POSTER 68

Zasocitinib (TAK-279), aA Oral, Allosteric, Highly Selective TYK2 Inhibitor, Reduced PASI Body Region and Individual Component Scores in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis

Tina Bhutani, Laura K. Ferris, Jessamyn Blau, Wenwen Zhang, Warren Winkelman, Melinda Gooderham

< Previous Poster | Next Poster >

Poster 68